Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

.2010 Jun;2(6):949-64.
doi: 10.4155/fmc.10.21.

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

Affiliations

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

Douglas S Johnson et al. Future Med Chem.2010 Jun.

Abstract

This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase. Covalent inhibitors have many desirable features, including increased biochemical efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compound. Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s). Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo. For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent. These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets. The substantial number of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small molecules. Emerging proteomic technologies offer a means to systematically discriminate safe (selective) versus deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism-based covalent inhibition via disulfide adduct formation.
Figure 2
Figure 2
Examples of covalent inhibitors including their protein target(s) with active-site nucleophile. The arrow indicates the position of attack by the nucleophile on the drug resulting in covalent modification of the target.
Figure 3
Figure 3. Assessment of global selectivity of covalent inhibitors by activity-based protein profiling (ABPP)
(A) Representative structure of an activity-based probe (ABP), which contains a reactive group, a linker or binding group and a reporter tag.(B) Competitive ABPP to determine the selectivity of an inhibitor against an enzyme family that is targeted by a particular ABP (with fluorescent reporter tag in this example). Probe-labeled proteins are analyzed by SDS-PAGE (in-gel fluorescence) and those that show significant reductions in fluorescent intensity in the presence of inhibitor are scored as targets of the inhibitor.(C) Click chemistry ABPP profiling to characterize the selectivity of covalent inhibitorsin vivo. Covalent inhibitors are converted to activity-based probes via incorporation of an alkyne handle and these probes are administered to living systems (cells or animals). Probe-labeled proteins are conjugated to rhodamine-azide using click chemistry and analyzed by SDS-PAGE (in-gel fluorescence).
Figure 4
Figure 4. Representative activity-based probes for individual enzyme families or subfamilies
Reactive groups are highlighted. Tag: Biotin, rhodamine, TAMRA, BODIPY or HA.
Figure 5
Figure 5. Representative photoreactive activity-based probes that achieve target selectivity through binding affinity and covalent labeling is accomplished by exposure to UV light
Tag: Biotin, rhodamine or TAMRA.
Figure 6
Figure 6
Covalent fatty acid amide hydrolase inhibitors; OL-135 is reversible.
Figure 7
Figure 7
Covalent inhibitors and clickable covalent probes emerging from chemoproteomic endeavors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Powers JC, Asgian JL, Ekici OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002;102:4639–4750. - PubMed
    1. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov. 2004;3:801–808. - PubMed
    1. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel. 2009;12:31–39. - PubMed
    1. Robertson JG. Mechanistic basis of enzyme-targeted drugs. Biochemistry. 2005;44:5561–5571. - PubMed
    1. Robertson JG. Enzymes as a special class of therapeutic target: clinical drugs and modes of action. Curr Opin Struct Biol. 2007;17:674–679. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp